Author
@OzmosiHealth OzmosiHealth
Real-time biotech catalyst and regulatory event feed across hundreds of clinical-stage names
Publishes a structured, link-backed stream of biotech/pharma
trader score
·
hit rate
·
mean α
·
signals 14d
277
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved +0.9% since posting (mean over 94 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | IBRX | @OzmosiHealth | +0.50 | ImmunityBio reported favorable Phase 3 ANKTIVA data, including 84% cystectomy avoidance at three years. | -10.5% | tweet ↗ |
| 2026-10-16 | RHHBY | @OzmosiHealth | +0.50 | FDA approved Roche's Enspryng as an at-home treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | NTHI | @OzmosiHealth | +0.25 | NeOnc reports an early compassionate-use improvement involving NEO100 in a child. | · | tweet ↗ |
| 2026-10-16 | RHHBY | @OzmosiHealth | +0.50 | FDA approved Roche's Enspryng as an at-home treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | REGN | @OzmosiHealth | +0.35 | CHMP recommended EU approval of an updated Libtayo dosing regimen across approved cancer types. | +1.8% | tweet ↗ |
| 2026-10-16 | TLSA | @OzmosiHealth | +0.15 | Tiziana dosed the final patient in a Phase 2 intranasal foralumab Alzheimer's trial. | · | tweet ↗ |
| 2026-10-16 | RHHBY | @OzmosiHealth | +0.50 | FDA approved Genentech's Enspryng as an at-home treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | RHHBY | @OzmosiHealth | +0.50 | FDA approved Genentech's Enspryng as an at-home treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | ASND | @OzmosiHealth | +0.35 | TransCon CNP received a positive CHMP opinion for treating pediatric achondroplasia. | +8.0% | tweet ↗ |
| 2026-10-16 | ATNM | @OzmosiHealth | +0.15 | Actinium announced EANM presentations covering broad preclinical antitumor activity of ATNM-400. | · | tweet ↗ |
| 2026-10-16 | ADIL | @OzmosiHealth | +0.10 | Adial appointed David Rubenstein as chief scientist to advance AT177. | · | tweet ↗ |
| 2026-10-16 | TNGX | @OzmosiHealth | +0.10 | Tango will present updated combination data at ESMO 2026. | +5.9% | tweet ↗ |
| 2026-10-16 | IONS | @OzmosiHealth | +0.35 | CHMP recommended TRYNGOLZA for EU approval in severe hypertriglyceridemia. | · | tweet ↗ |
| 2026-10-16 | OMER | @OzmosiHealth | -0.50 | CHMP issued a negative opinion after re-examining narsoplimab's European authorization application. | · | tweet ↗ |
| 2026-10-15 | SNDX | @OzmosiHealth | +0.10 | Syndax's Revuforj was named to TIME's Best Inventions of 2026 list. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.